Patrick Vermersch, MD, PhD - Stripped Back: CNS Inflammation and the Potential for Meaningful Therapeutic Progress in Non-Relapsing Forms of Multiple Sclerosis
Update: 2025-10-30
Description
Visit https://www.peervoice.com/HQU860 to view the entire programme with slides. After completing “Patrick Vermersch, MD, PhD - Stripped Back: CNS Inflammation and the Potential for Meaningful Therapeutic Progress in Non-Relapsing Forms of Multiple Sclerosis”, participants will be able to: Recognise the unmet needs and limitations of current treatment approaches in addressing disability and disease progression in patients with non-relapsing forms of multiple sclerosis (MS); Describe the mechanistic rationale for emerging therapies (eg, Bruton tyrosine kinase inhibitors [BTKi] and anti-CD40 ligand [CD40L] monoclonal antibodies) in the context of the pathophysiological drivers of central nervous system inflammation in primary progressive and non-relapsing secondary progressive MS; Discuss the design and patient populations associated with clinical trials examining emerging therapies in primary progressive and non-relapsing and secondary progressive MS; and Appraise the data from trials examining the safety and efficacy of emerging therapies (eg, BTKi and anti-CD40L monoclonal antibodies) in primary progressive and non-relapsing secondary progressive MS.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
